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characterization of the fecal 
microbiome in cats with 
inflammatory bowel disease or 
alimentary small cell lymphoma
Sina Marsilio1,2*, Rachel pilla1, Benjamin Sarawichitr1, Betty chow  3,6, Steve L. Hill3,7, 
Mark R. Ackermann4, J. Scot estep5, Jonathan A. Lidbury1, Joerg M. Steiner1 & 
Jan S. Suchodolski1
Feline chronic enteropathy (CE) is a common gastrointestinal disorder in cats and mainly comprises 
inflammatory bowel disease (IBD) and small cell lymphoma (SCL). Both IBD and SCL in cats share 
features with chronic enteropathies such as IBD and monomorphic epitheliotropic intestinal 
T-cell lymphoma in humans. The aim of this study was to characterize the fecal microbiome of 38 
healthy cats and 27 cats with CE (13 cats with IBD and 14 cats with SCL). Alpha diversity indices 
were significantly decreased in cats with CE (OTU p = 0.003, Shannon Index p = 0.008, Phylogenetic 
Diversity p = 0.019). ANOSIM showed a significant difference in bacterial communities, albeit with a 
small effect size (P = 0.023, R = 0.073). Univariate analysis and LEfSE showed a lower abundance of 
facultative anaerobic taxa of the phyla Firmicutes (families Ruminococcaceae and Turicibacteraceae), 
Actinobacteria (genus Bifidobacterium) and Bacteroidetes (i.a. Bacteroides plebeius) in cats with CE. The 
facultative anaerobic taxa Enterobacteriaceae and Streptococcaceae were increased in cats with CE. No 
significant difference between the microbiome of cats with IBD and those with SCL was found. Cats with 
CE showed patterns of dysbiosis similar to those in found people with IBD.
Feline chronic enteropathy (CE) is common in elderly cats and is defined as the presence of clinical signs of 
gastrointestinal disease for more than 3 weeks in the absence of infectious intestinal diseases (e.g., parasites) and 
extraintestinal causes (e.g., renal disease, hyperthyroidism)1.
Feline CE mainly comprises inflammatory bowel disease (IBD) and small cell lymphoma (SCL)2–4.
Diagnosis and differentiation can be challenging as clinical signs might be virtually the same in both disease 
entities2,5. A clinical diagnosis of IBD in cats is based on the presence of chronic gastrointestinal signs of at least 3 
weeks duration, the absence of known enteropathogens or other causes of signs of gastrointestinal disease, and the 
histopathologic confirmation of intestinal inflammation6. Thus, the diagnosis of IBD and the differentiation from 
SCL requires histopathologic examination of tissue biopsies collected under general anesthesia7,8. In cases where 
histopathology results are ambiguous, additional diagnostic modalities such as immunohistochemistry and clon-
ality testing are indicated3,4,9,10. Hence, the diagnosis of IBD and SCL is elaborate, expensive, time- and resource 
consuming and invasive. Treatment of IBD and SCL is usually based on immunosuppression using various ster-
oids and cytotoxic medication such as chlorambucil or cyclosporine2,6,11. Therefore, less invasive diagnostic and 
treatment modalities would be highly desirable.
The intestinal microbiome plays a substantial role in modulating the host’s immune system within and beyond 
the gastrointestinal tract. Studies in people12–14 and dogs15–17 with IBD have found alterations in the composition 
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of the intestinal microbiome that might impair the host’s health status. These changes are commonly referred to 
as dysbiosis14. Despite variations among studies, species, and individuals, common themes characterize intestinal 
dysbiosis. Across different species, three main hallmarks of dysbiosis have been described: a reduction in overall 
bacterial diversity (alpha diversity)15,18–20, a decreased stability of microbial communities and thus a higher fluctu-
ation rate over time21, and a reduction in obligately anaerobic taxa of the phyla Firmicutes and Bacteroidetes at the 
expense of an increase in facultative anaerobes, including members of the family Enterobacteriaceae15,17–19,21–24. 
Dysbiosis has been described in people with various forms of enteropathy, including ulcerative colitis, Crohn’s 
disease, and colorectal cancer, and it might be a driver or consequence of chronic inflammation and malignant 
transformation25. Feline IBD and SCL share some features with chronic enteropathies in people. Both human 
and feline IBD is characterized by chronic inflammatory changes in the gastrointestinal tract3,26. Feline SCL is 
characterized by a monomorphic infiltration of the intestinal mucosa with small to medium lymphocytes, mostly 
in the small intestine and is often associated with epitheliotropism4. This histologic appearance resembles that 
of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) in people, formerly known as enteropathy 
associated T-cell lymphoma Type 2 (EATL Type 2)27,28. Whereas SCL is quite common in cats, MEITL is rare in 
people, and thus large intersectional studies are scarce28. Both IBD and SCL occur spontaneously and frequently 
in cats, and thus the cat could be an interesting model for IBD or MEITL in people.
Several studies have characterized the fecal microbiome in cats with acute and chronic diarrhea18,29. However, 
in previous studies the cats were categorized based on clinical signs without confirmation of the underlying dis-
ease process. This study aimed to characterize and compare the fecal microbiome in healthy cats and cats with 
histopathologically confirmed CE (IBD or SCL).
Results
Animal demographics and clinical activity index. A total of 65 cats were enrolled into this study, 38 
healthy cats and 27 cats with chronic enteropathy (13 with IBD and 14 with SCL). A fecal sample was collected 
from all cats. Demographic characteristics are shown in Table 1.
Age did not differ significantly between healthy cats (median age: 9 years, range: 1–15 years) and cats with CE 
(median age: 10 years, range: 2–16 years; P = 0.052). Cats with CE had a significantly lower body weight (median: 
4.6 kg, range: 2.9–10.5 kg) and body condition score (BCS; median: 4, range: 1–9) than healthy cats (median body 
weight: 5.4 kg, range: 2.5–8.6 kg, median BCS: 5, range: 4–9; P = 0.035 and P < 0.001, respectively). Cats with SCL 
were significantly older (median age: 11.5 years, range: 7–16 years) than cats with IBD (median age: 8 years, range: 
2–16; P = 0.028). Cats with IBD and cats with SCL did not show statistically significant differences with regard to 
sex (p = 0.816), body weight (p = 0.454), and BCS (p = 0.529). Cats with CE had a median feline chronic enter-
opathy activity index (FCEAI)1 score of 5 (range: 2–11). FCEAI did not differ between cats with IBD (median: 6, 
range: 3–11) and cats with SCL (median: 5, range: 2–10; p = 0.838).
Sequence analysis and rarefaction. In total, the sequence analysis of the 65 fecal samples yielded 
2,837,900 quality sequences (median per sample: 73,741; range: 43,660–145,373).
Alpha diversity at a depth of 43,660 sequences, as described by observed OTUs, Shannon Diversity Index, 
and Faith Phylogenetic Diversity Index, was significantly lower in cats with CE than in healthy cats (P = 0.003, 
P = 0.008, and P = 0.019, respectively; Fig. 1). In addition, alpha diversity appeared to continuously decrease from 
healthy cats, over cats with IBD to cats with SCL (Results for Kruskal Wallis ANOVA: observed OTUs P = 0.015, 
Shannon index P = 0.030, Phylogenetic Diversity Index P = 0.049). However, alpha diversity indices did not differ 
significantly between cats with IBD and cats with SCL. Detailed results for alpha diversity indices are shown in 
Supplementary Table 1.
Microbial communities. Although cats with CE showed no obvious visible clustering on Principal 
Component Analysis (PCoA) compared to healthy cats, a statistically significant difference between the two 
groups was found based on ANOSIM of unweighted Unifrac distances (P = 0.023, R = 0.073: Fig. 2A). Individual 
bacterial groups were analyzed using a Kruskal Wallis test. Taxa found to be significantly different before correc-
tion for the false discovery rate (FDR) are listed in Table 2. Within the phylum Firmicutes, bacterial taxa belong-
ing to the family Ruminococcaceae (unclassified species of the genus Oscillospira) and members of the genus 
Turicibacter (class Bacilli, order Turicibacterales, family Turicibacteraceae) were significantly less abundant in cats 
Healthy Feline CE p value
number of cats 38 27
median age in years (range) 9 (1–15) 10 (2–16) 0.052
median body weight in kg (range) 5.4 (2.5–8.6) 4.6 (2.9–10.5) 0.035
median body condition score (range) 5 (4–9) 4 (1–9) <0.0001
sex 18 FS, 20 MN 11 FS, 16 MN 0.596
breeds
22 DSH, 4 DLH, 2 Maine Coon, 2 Persian, 1 Bombay, 
1 Burmese, 1 DMH, 1 Norwegian Forest Cat, 1 Lynx, 
1 mixed breed, 1 Sphinx
17 DSH, 3 DMH, 3 Siamese, 2 
DLH, 1 Rag Doll, 1 mixed breed
Table 1. Comparison of demographic data between healthy cats and cats with feline chronic enteropathy 
(FCE). Abbreviations: FS female spayed, MN male neutered, DSH domestic shorthair, DLH domestic longhair, 
DMH domestic medium hair.
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with CE than in healthy cats. In addition, cats with CE had significantly decreased bacterial populations belonging 
to members of the phyla Bacteroidetes (one undetermined species and Bacteroides plebeius) and Actinobacteria 
(genus Bifidobacterium). In contrast, members of the families Enterobacteriaceae and Streptococcaceae were sig-
nificantly more abundant in feces from cats with CE. However, although trends were noted, no statistically sig-
nificant differences were found after correction for FDR. Figure 2B–F depicts results of the statistical analysis for 
some selected taxa.
Conversely, based on Linear Discriminant Analysis Effect Size (LEfSe), bacteria of the families 
Bifidobacteriaceae, Ruminococcaceae, Turicibacteriaceae, and Paraprevotellaceae were associated with feces from 
healthy cats, while Enterobacteriaceae and Streptococcaceae were associated with those of cats with CE. A detailed 
summary of the LEfSe results can be found in Table 3.
Effect of disease subtype on the feline fecal microbiota. Similar to alpha-diversity, beta-diversity 
showed continuous changes when comparing healthy cats, cats with IBD, and cats with SCL, with sequential 
increases or decreases of relative percentages between groups. According to Kruskal Wallis tests, the abundance of 
Figure 1. Alpha diversity indices at a depth of 43.660 sequences. (A) Observed OTUs. (B) Shannon Diversity 
Index. (C) Faith Phylogenetic Diversity Index. Figures on the left show the comparison between healthy cats 
and cats with chronic enteropathy (FCE). Figures on the right show the comparison between different the CE 
subgroups, inflammatory bowel disease (IBD) and small cell lymphoma (SCL). The top dashed line represents 
the Kruskal Wallis ANOVA comparison, solid parentheses represent post hoc multiple comparisons using 
Dunn’s test.
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members of the genus Bifidobacterium (class Actinobacteria) differed significantly among the three groups, with 
highest numbers in healthy cats and lowest numbers in cats with SCL. In contrast, bacteria within the families 
Enterobacteriaceae (phylum Proteobacteria) and Streptococcaceae (phylum Firmicutes) serially increased from 
healthy cats, to cats with IBD to cats with SCL. However, after correction for the false discovery rate (FDR), none 
of the differences remained statistically significant. In addition, no significant differences in microbial commu-
nities between cats with IBD and cats with SCL were observed. A detailed summary of relative percentages of the 
most abundant bacterial groups appears in Supplementary Table 2.
Discussion
To our knowledge, this is the first study comparing the fecal microbiome in a cohort of cats with histopathologi-
cally confirmed spontaneous CE to that of clinically healthy cats using untargeted Illumina sequencing analysis. 
Alpha diversity was significantly lower in cats with CE than in healthy cats. In particular, cats with CE tended to 
show a lower abundance of obligately anaerobic members of the phyla Firmicutes (family Ruminococcaceae and 
Turicibacteraceae), Bacteroidetes (e.g. Bacteroides plebeius and unclassified species), and Actinobacteria (genus 
Bifidobacterium). In contrast, facultative anaerobes such as Enterobacteriaceae and Streptococcaceae tended to 
be more abundant in cats with CE than in healthy cats. However, although we found differences in abundance 
of various bacterial taxa between different groups of cats, there were no statistically significant differences after 
correction for FDR. Nevertheless, the trends found in our cohort of cats mirror common patterns of fecal and 
mucosal dysbiosis described in other species such as humans19,21–24 and dogs15,17,30, i.e. decreased bacterial diver-
sity, decreased members of obligate anaerobes (Firmicutes and Bacteroidetes) and increased facultative anaerobes 
(especially of the family of Enterobacteriaceae). Dysbiosis has been documented in humans with various enter-
opathies, such as IBD (ulcerative colitis and Crohn’s disease), antibiotic-associated diarrhea, necrotizing entero-
colitis, and colorectal cancer14,31 and also in dogs with chronic enteropathies16,30,32. Dysbiotic patterns appear to 
be similar across different forms of enteropathy; however, because the rarity of the disease, there are no studies 
published on the microbiomes of people with MEITL. A recent study analyzing the microbiome in feces from 
dogs with IBD or intestinal lymphoma compared to healthy dogs found dysbiosis to be associated with both 
disease entities32. Similar to the current study, the authors used an untargeted Illumina sequencing approach to 
characterize the fecal microbiome. The authors reported an increased abundance of Coprococcus, Oscillospira, 
Figure 2. (A) Beta diversity. Principal coordinate analysis (PCoA) of unweighted UniFrac distances of 16S 
rRNA genes. Analysis of similarity (ANOSIM) revealed significantly different between healthy cats and cats 
with chronic enteropathy (P = 0.023, R = 0.073), although with a small effect size and no visible clustering. 
Healthy cats are depicted as blue, cats with inflammatory bowel disease (IBD) as yellow, and cats with small cell 
lymphoma (SCL) as red dots. (B–F) Univariate analysis of relative percent abundance of selected taxa. Members 
of the family Ruminococcaceae, of the genus Bifidobacterium and the species Bacteroides plebeius were found to 
be lower in cats with chronic enteropathy (CE) compared to healthy cats. Members of the genus Streptococcus 
and the family Enterobacteriaceae were found to be higher in cats with CE compared to healthy cats.
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and Eubateria in dogs with intestinal lymphoma compared to healthy dogs. These findings might indicate species 
differences in disease phenotype and etiopathogenesis.
One universal activity of the intestinal microbiome is the metabolism and fermentation of carbohydrates 
into short chain fatty acids, such as acetate, butyrate, and propionate. Members of the phylum Firmicutes are 
mostly anaerobic and have been shown to exert indirect anti-inflammatory and immune-modulatory effects 
by producing short chain fatty acids, particularly butyrate14. Butyrate is the major energy source of colono-
cytes33, thereby contributing to epithelial cell proliferation and repair and to intestinal barrier integrity34. In 
addition, evidence exists that butyrate may exhibit anti-inflammatory and anti-carcinogenic properties35,36. 
The main butyrate-producing bacteria in the human colon are members of the families Lachnospiraceae and 
Ruminococcaceae (phylum Firmicutes), and their fecal abundance in people is often depleted in dysbiotic states, 
including UC and CD21,37. Our report appears to be the first to show a depletion of butyrate-producing bacteria 
Bacterial Group
Healthy FCE Healthy vs. FCE
Median Range Median Range Pvalue Qvalue
Class
Actinobacteria 1.2 0–36.8 0.2 0.1–38.9 0.0466 0.2563
Bacteroidia 25.3 1.2–56.4 16.6 0.7–55.3 0.0458 0.2563
Order
Bifidobacteriales 1.2 0–36.8 0.2 0.1–38.9 0.0316 0.14885
Bacteroidales 25.3 1.2–56.4 16.6 0.7–55.3 0.0458 0.14885
Turicibacterales 0 0–23.7 0 0–5.8 0.0344 0.14885
Enterobacteriales 0.1 0–32.6 0.4 0–39.4 0.0098 0.1274
Family
Bifidobacteriaceae 1.2 0–36.8 0.2 0.1–38.9 0.0316 0.16053333
Prevotellaceae 1.1 0–21.7 0.5 0–22.5 0.0519 0.1827
Odoribacteraceae 0 0–2.8 0.1 0–1.4 0.0522 0.1827
Paraprevotellaceae 0 0–18.5 0 0–5.6 0.0022 0.0616
Streptococcaceae 0 0–4.1 0.1 0–61.4 0.0059 0.0826
Turicibacteraceae 0 0–23.7 0 0–5.8 0.0344 0.16053333
Ruminococcaceae 8 1.2–18.4 5.7 0.2–17.3 0.0228 0.1596
Enterobacteriaceae 0.1 0–32.6 0.4 0–39.4 0.0098 0.09146667
Genus
Bifidobacterium 1.2 0–36.8 0.2 0.1–38.9 0.0316 0.2021
Prevotella 0 0–18.5 0 0–5.6 0.0182 0.17108
Streptococcus 0 0–4.1 0.1 0–61.4 0.0037 0.08695
Turicibacter 0 0–23.7 0 0–5.8 0.0344 0.2021
Undetermined genus, Peptostreptococcaceae 0.3 0–16.6 0.1 0–5.9 0.04 0.20888889
Undetermined genus, Ruminococcaceae 0.1 0–0.9 0 0–0.5 0.0033 0.08695
Oscillospira 1.1 0.1–3.5 0.7 0–2.2 0.0181 0.17108
Undetermined genus, Erysipelotrichaceae 0.1 0–0.9 0 0–0.8 0.0241 0.18878333
Undetermined genus, Enterobacteriaceae 0.1 0–32.6 0.4 0–39.4 0.0081 0.1269
Species
Undetermined species, Bifidobacterium 1.1 0–35.2 0.2 0–38.6 0.0234 0.13737
Undetermined species, Bacteroides 0.1 0–2.3 0 0–0.8 0.0041 0.058425
Undetermined species, Bacteroides 10.8 0.3–51 6.5 0.3–47.4 0.3514 0.5271
Bacteroides plebeius 1.2 0–14.5 0.1 0–10.9 0.0039 0.058425
Undetermined species, Prevotella 0 0–18.5 0 0–5.6 0.0182 0.129675
Undetermined species, Enterococcaceae 0.1 0–5 0 0–1.7 0.1968 0.37791
Undetermined species, Streptococcus 0 0–4.1 0.1 0–61.4 0.0109 0.10355
Undetermined species, Turicibacter 0 0–23.7 0 0–5.8 0.0344 0.1691
Undetermined species, Clostridium 0.2 0–10.8 0.9 0.1–20.3 0.0022 0.058425
Undetermined species, Ruminococcus 0 0–3.2 0.6 0–2.5 0.0356 0.1691
Undetermined species, Peptostreptococcaceae 0.3 0–16.6 0.1 0–5.9 0.04 0.17538462
Undetermined species, Ruminococcaceae 0.1 0–0.9 0 0–0.5 0.0033 0.058425
Undetermined species, Oscillospira 1.1 0.1–3.5 0.7 0–2.2 0.0181 0.129675
Undetermined species, Erysipelotrichaceae 0.1 0–0.9 0 0–0.8 0.0241 0.13737
Undetermined species, Enterobacteriaceae 0.1 0–32.6 0.4 0–39.4 0.0081 0.09234
Table 2. Taxa found to be significantly different (p value) between healthy cats and cats with chronic 
enteropathy (FCE) before correction for false discovery (q value). Numbers represent relative percentages.
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in cats with CE. Determining the association between the fecal abundance of Ruminococcaceae and butyrate con-
centration in cats with CE might further elucidate the function of this taxon in cats with CE.
Another major hallmark of dysbiosis involves members of the phylum Bacteroidetes. Bacteroidetes are highly 
abundant in the healthy microbiome but are decreased in the mucosal or fecal microbiome from humans and 
dogs with various forms of enteropathy17,19,22. Interestingly, Bacteroides plebeius has been found to be strongly 
associated with remission in people with CD38. In our cohort, Bacteroidetes and specifically Bacteroides plebeius 
tended to be decreased in cats with CE. Investigating the association between disease outcome and abundance of 
Bacteroides plebeius might be of interest for future studies in cats with CE.
Our study showed a trend towards a decreased abundance of Bifidobacteria in cats with IBD and SCL. 
Bifidobacteria are also commonly decreased in fecal and mucosal samples from human patients with IBD14,39. 
Various Bifidobacteria strains have been shown to exert anti-inflammatory properties by regulating immune cells 
and cytokine networks40 and by directly and indirectly enhancing intestinal barrier function41,42. For instance, 
Bifidobacterium strains have been shown to induce IL-10 producing regulatory T-cells43,44 and to exert immunoin-
hibitory effects by interacting with Toll-like receptor-245. Therefore, Bifidobacteria have become an attractive thera-
peutic target and are often used in probiotic formulations46. Our study confirms findings of a previous study utilizing 
fluorescence in situ hybridization, where Bifidobacteriaceae were reported to be decreased in fecal samples in cats 
with IBD. To the authors’ knowledge, such a decrease has not been documented in dogs. This highlights the differ-
ence between species and might point toward Bifidobacteria as potential therapeutic targets in cats with CE.
Level Selected Taxa
Associated 
Group
LDA 
Score
Associated 
Subgroup
LDA 
Score
Phylum Bacteroidetes Healthy 4.797 None NA
Class
Actinobacteria Healthy 4.562 Healthy 4.662
Bacteroida Healthy 4.74 None NA
Order
Bifiodobacteriales Healthy 4.196 Healthy 4.659
Turicibacterales Healthy 4.356 None NA
Enterobacteriales FCE 4.302 None NA
Bacteroidales Healthy 4.549 None NA
Family
Streptococcaceae FCE 4.229 SCL 4.425
Ruminococcaceae Healthy 4.204 None NA
Bifidobacteriaceae Healthy 4.227 Healthy 4.394
Enterobacteriaceae FCE 4.256 None NA
Paraprevotellaceae Healthy 4.009 Healthy 4.116
Turicibacteraceae Healthy 4.04 None NA
Odoribacteraceae None NA SCL 4.289
Prevotellaceae None NA Healthy 3.851
Genus
Erysipelotrichaceae Healthy 3.672 None NA
Oscillospira Healthy 3.534 None NA
Peptostreptococcaceae (unclassified) Healthy 3.594 None NA
Bifidobacterium Healthy 4.293 Healthy 4.496
Turicibacter Healthy 3.632 None NA
Streptococcus FCE 4.119 SCL 4.511
Paraprevotella Healthy 3.789 None NA
Enterobacteriaceae (unclassified) FCE 4.226 None NA
Prevotella Healthy 4.109 Healthy 4.304
Coriobacteriaceae (unclassified) None NA IBD 4.187
Species
Turicibacter (unclassified) Healthy 3.578 None NA
Streptococcus (unclassified) FCE 4.092 SCL 4.494
Oscillospira (unclassified) Healthy 3.509 None NA
Bacteroides plebeius Healthy 4.069 Healthy 4.285
Enterobacteriaceae (unclassified) FCE 4.255 None NA
Paraprevotella (unclassified) Healthy 3.465 None NA
Peptostreptococcaceae (unclassified) Healthy 3.652 None NA
Bifidobacterium (unclassified) Healthy 3.972 None NA
Erysipelotrichaceae (unclassified) Healthy 3.626 None NA
Prevotella copri None NA Healthy 4.258
Coriobacteriaceae (unclassified) None NA SCL 4.169
Table 3. Linear discriminant analysis effect size (LEfSE) analysis of 16S rRNA gene sequences. LEfSE was 
calculated for healthy cats vs. cats with chronic enteropathy (FCE) and in a second step for the subgroups of 
FCE, inflammatory bowel disease (IBD) and small cell lymphoma (SCL). The Linear Discriminant Analysis 
Score (LDA) is given as log 10. Only the taxa meeting a significant LDA threshold value of >2 are shown.
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Besides a decrease in obligate anaerobic bacteria, dysbiosis is commonly characterized by an increase in faculta-
tive anaerobic bacteria, specifically members of the family of Enterobacteriaceae14,47,48. This phenomenon might be 
explained by the oxygen gradient model49,50. In this model it is hypothesized that during a steady state, the mucosal 
microbiome is controlled by mucosal immune responses, the intestinal barrier, and competition with luminal bacteria. 
The intestinal mucosa shows an oxygen gradient, in which the mucosal interface is mostly aerobic while the lumen is 
mostly anaerobic. It is thought that during inflammation, the intestinal barrier breaks downs, thereby increasing the 
luminal oxygen tension. This leads to a translocation and expansion of aerotolerant taxa usually located close to the 
mucosa centripetal into the lumen and centrifugal across the epithelial barrier into the lamina propria, contributing to 
the inflammatory response49,50. Our cohort of cats followed this pattern, with a trend of higher abundance of facultative 
anaerobic taxa, specifically Enterobacteriaceae and Streptococcaceae. Both taxa typically consist of facultative anaerobic 
members and thus might thrive with increased luminal oxygen tension. An increased abundance of Streptococcaceae 
has previously been documented in feces from people and dogs with IBD51,52.
Our study has several limitations. With regards to enrollment criteria, of 38 control cats enrolled into this 
study, 22 cats underwent a physical examination and laboratory testing to verify their health status, while 16 cats 
were classified as healthy based on owner responses to a questionnaire alone. In addition, a clinical diagnosis of 
IBD was based on the presence of chronic gastrointestinal signs of at least 3 weeks duration, the absence of known 
enteropathogens or other causes of signs of gastrointestinal disease, and the histopathologic confirmation of 
intestinal inflammation6. Thus, food-responsive enteropathy was not excluded in all of the enrolled cats. However, 
many human patients with IBD show complete or partial responses to dietary interventions without being reclas-
sified as having food-responsive enteropathy53–56. Our study aimed to characterize clinically relevant differences 
between the fecal microbiome of cats with CE when compared to healthy control cats. We controlled for demo-
graphic characteristics such as age, sex, and breed. Environmental factors, such as housing, diet, previous parasitic 
or systemic infections etc. were not controlled for in this study, as it would have affected the clinical relevance of 
the results. This concept is supported by recent studies showed that standardization in is a major source of poor 
reproducibility of preclinical trials57,58.
With regards to results of this study, the following limitations have to be acknowledged. Although, we found 
differences in the abundance of various bacterial taxa between different groups of cats, there were no statisti-
cally significant differences after correction for FDR, and thus differences did not appear to be as strong as they 
have been reported for humans and dogs. This phenomenon might be explained by the different disease phe-
notypes. Whereas diarrhea is the predominant clinical sign of chronic enteropathy in humans59 and dogs60,61, it 
is less common in cats, in which weight loss, hyporexia, and vomiting are the dominant clinical signs of CE1,2. 
In our cohort of cats, only 5 out of 27 cats showed diarrhea. The reason for the different disease phenotypes in 
humans, dogs, and cats is not entirely clear, but factors may include different disease localization (i.e. small vs. 
large bowel) and different disease pathophysiology. Cats often show involvement of the small intestinal tract1,2,4, 
but the fecal microbiome represents predominantly bacterial communities present in the distal part of the intes-
tinal tract62. In addition, the fecal microbiome might not accurately represent the mucosa-associated microbi-
ome62. Therefore, investigating the luminal content within the small intestine or the mucosal microbiome might 
reveal more distinct differences in microbial communities in cats than this study of fecal samples. However, a 
recent study comparing the fecal and mucosal microbiomes in human patients with and without IBD found large 
overlaps between the two microbial habitats in each group49. Although it is important to point out that IBD in 
humans is predominantly a large bowel disease. A recent study, comparing the mucosa associated microbiome in 
cats with CE using targeted analysis by fluorescence in situ hybridization found significantly increased numbers 
of Bacteroides spp. in ileal biopsies from cats with SCL compared to biopsies from cats with IBD63. These findings 
further underline possible differences between intestinal compartments (small vs. large bowel) and media (e.g. 
fecal vs mucosa-associated microbiome). We also cannot exclude that a larger sample size would have revealed 
statistically significant differences after FDR correction. Finally, the mode and speed of fecal collection and pro-
cessing was slightly different between groups and individuals and might have had an effect on our results.
Differentiation of IBD from SCL in cats can be challenging as clinical signs as well as intestinal mucosal changes 
can be overlapping3. In addition, mucosal changes can have an uneven distribution, inflammation and neoplastic 
lesions can coexist might and it has been suggested that inflammatory lesions might progress to lymphoma over 
time3,4. Hence, every classification into groups of IBD and SCL is associated with a degree of uncertainty. However, 
all cats in the CE group underwent gastoduodenoscopy and ileoscopy. In addition, immunohistochemistry and 
clonality testing were applied, where indicated, to ensure the maximum accuracy ion class assignment.
Today, histopathology, immunohistochemistry and clonality testing on intestinal samples is considered to be 
the gold standard for the differentiation of inflammatory from neoplastic lesions10. However, histopathological 
examination of intestinal tissue biopsies from dogs and cats is associated with a high inter-observer variability64. 
In addition, a recent study showed that healthy elderly cats can also have abnormal histopathological findings 
without any apparent clinical significance65. Therefore, alternative methods for the diagnosis and differentia-
tion of feline IBD and SCL would be desirable. We did not find any bacterial taxa in which abundance differed 
significantly between cats with IBD and SCL. However, as a striking pattern many bacterial taxa appeared to 
either serially increase (e.g., Enterobacteriaceae) or decrease (e.g., Actinobacteria, Bifidobacteria, Prevotella) when 
comparing to healthy cats, cats with IBD, and cats with SCL. Similarly, progression of IBD to SCL over months to 
years has long been suspected, and inflammatory lesions frequently coexist with SCL4,9. Our findings might lend 
support to the hypothesis that IBD and SCL are not two different diseases but rather a continuum.
In summary, we found that cats with CE show patterns of dysbiosis that have previously been described in 
people with IBD. Obligately anaerobic taxa in the phyla Firmicutes, Bacteroidetes, and Actinobacteria were 
depleted in cats with CE, while facultative anaerobes such as Enterobacteriaceae and Streptococcaceae were more 
abundant. Bacteroides plebeius, a species shown to be associated with positive outcome in people with CD, was 
decreased in our cohort of cats.
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Methods
Animals. This prospective study was conducted at the Veterinary Medical Teaching Hospital at Texas 
A&M University between May 2015 and September 2017. The study protocol was approved by the Texas A&M 
University Institutional Animal Care and Use Committee and all methods were performed in accordance with 
relevant guidelines and regulations.
The health status of cats in the group considered healthy was verified by an owner questionnaire on gen-
eral and gastrointestinal health. The questionnaire covered the following areas: attitude/activity, appetite, 
drinking, urination, chronic illnesses, weight loss, vomiting, diarrhea, and treatment with antibiotics, antacids, 
anti-inflammatory drugs, or steroids. In 22 cats, physical examination was performed by a single board-certified 
internist (SM). The body condition score was assessed using a previously established a nine-point condition 
scoring system66. Blood was collected from a peripheral vein or the jugular vein and the following tests were 
performed: complete blood count, serum chemistry profile, total T4, cobalamin, folate, feline pancreatic lipase 
immunoreactivity (fPLI), and feline trypsin-like immunoreactivity (fTLI). Cats with gastrointestinal signs 
(weight loss, hyporexia, vomiting > 2x/ month, diarrhea) within 6 months prior to enrollment were excluded. 
In addition, cats with systemic diseases, chronic illnesses or clinically significant laboratory abnormalities were 
excluded from the study. Finally, cats that had received any antibiotics, antacids, anti-inflammatory drugs, or 
corticosteroids within the past 6 months were excluded.
Cats with clinical signs of chronic enteropathy (weight loss, hyporexia, vomiting, diarrhea) of at least 3 weeks 
duration were eligible for enrollment into the CE group. Cats in this group were either presented to the Small 
Animal Hospital at Texas A&M University, College Station, Texas, or the Veterinary Specialty Hospital, San Diego, 
California. Extra-gastrointestinal disease as well as possible infectious intestinal diseases were excluded based on 
a complete blood count, serum chemistry profile, total T4 and fecal examination. All cats in this group under-
went gastro-duodenoscopy and ileo-colonoscopy for diagnostic purposes. Histopathologic examination of H&E 
stained endoscopic formalin-fixed, paraffin-embedded (FFPE) tissue sections was performed by board-certified 
pathologists (MA or JSE) blinded to the clinical status of the cats.
Cases with a histopathological diagnosis of SCL or in which the pathologist was suspicious of an underlying 
SCL underwent additional diagnostic testing with immunohistochemistry and PCR for antigen receptor rear-
rangement testing for diagnostic confirmation. A final diagnosis of IBD or SCL was reached upon integration of 
results from histopathology, immunohistochemistry, and PARR based on the current EuroClonality/BIOMED-2 
guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations10,67,68. 
Cats that had received antibiotics within 4 weeks or corticosteroids within the past 2 weeks prior to fecal sampling 
were excluded from the study.
Spontaneously passed fecal samples were collected from healthy cats, refrigerated and shipped to the Texas 
A&M Gastrointestinal Laboratory within 24 hours of passing. Fecal samples from cats with CE were either col-
lected after spontaneous void or digitally while the cat was under anesthesia for endoscopy. All samples were 
shipped on cold packs or on dry ice. Upon arrival, fecal samples were immediately transferred to a lysis buffer and 
DNA was extracted using the Mobio Power Soil DNA Extraction kit (MoBio Laboratories, Inc., CA) following 
manufacturer’s instructions.
Amplification and sequencing of the V4 variable region of the 16 S rRNA gene were performed utilizing the 
Illumina MiSeq Sequencing platform. Sequencing was performed at MR DNA (Shallowater, TX, USA) following 
the manufacturer’s guidelines using forward and reverse primers: 515 F (5′-GTGCCAGCMGCCGCGGTAA-3′) 
and 806 R (5′- GGACTACVSGGGTATCTAAT-3′). Briefly, the PCR reaction was performed in a single-step 28 
cycle PCR using the HotStarTaq Plus Master Mix Kit (Qiagen, USA) under the following conditions: 94 °C for 
3 minutes, followed by 28 cycles (5 cycles used on PCR products) of 94 °C for 30 seconds, 53 °C for 40 seconds and 
72 °C for 1 minute, after which a final elongation step at 72 °C for 5 minutes was performed. After sequencing, 
barcodes and primers were removed from the sequences; then short (<150 bp), ambiguous, homopolymeric, and 
chimeric sequences were depleted from the dataset. Operational Taxonomic Units (OTUs) were assigned based 
on at least 97% sequence similarity using the QIIME 2.0 pipeline69. Sequences assigned as chloroplast, mitochon-
dria and Unassigned were removed before downstream analysis. Additionally, OTUs assigned to the phylum 
cyanobacteria were considered to be potential plant chloroplast contaminants and excluded from the analysis. 
Sequences were rarefied to an equal depth of 12,000 sequences per sample. The sequences were deposited in SRA 
under accession number SRP168128.
Statistical analysis. All datasets were tested for normality using the Shapiro-Wilk test (JMP 10, SAS soft-
ware Inc.). Differences in bacterial communities between healthy cats and cats with CE were analyzed using the 
phylogeny-based unweighted UniFrac distance metric, and PCoA plots and rarefaction curves were generated 
within QIIME69. ANOSIM (Analysis of Similarity) within the software package PRIMER 6 (PRIMER-E Ltd., 
Luton, UK) was used to determine significant differences in microbial communities between healthy cats and dis-
eased cats. Because most datasets did not meet the assumptions of normal distribution, statistical testing between 
healthy and diseased cats were performed using non-parametric Kruskal-Wallis tests or a Mann-Whitney U 
test where applicable. The resulting p-values were adjusted for multiple comparisons using the Benjamini & 
Hochberg’s False Discovery Rate (FDR), and an adjusted q < 0.05 was considered statistically significant70. A 
Dunn’s post-test was used to determine which disease types differed significantly. Linear discriminant analysis 
Effect Size (LEfSe) was used to elucidate bacterial taxa (16 S rRNA genes) associated with healthy or diseased cats. 
LEfSe was used online in the Galaxy workflow framework.
The data that support the findings of this study are available from the corresponding author (SM) upon rea-
sonable request.
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